Compare Moderna, Inc. (MRNA) vs Morgan Stanley (MS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Morgan Stanley — how do they compare? Moderna, Inc. trades at $137.99 (market cap $56.02B), while Morgan Stanley trades at $216.93 (market cap $339.62B). The key difference: Morgan Stanley is far larger — about 6.1× Moderna, Inc.'s market cap, and Morgan Stanley pays a 2.13% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | MS | |
|---|---|---|
Market Cap | $56.02B | $339.62B |
Sector | Health | Financials |
52-Week High | $174.38 | $228.42 |
52-Week Low | $22.36 | $151.86 |
Enterprise Value | $52.17B | — |
Dividend Yield | — | 2.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.
The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.
Morgan Stanley (MS) trades at $215.33, down 1.09% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $239.58. Revenue grew to $66.0 billion in 2025, with net income margin expanding to 25.56%, and the company has beaten EPS estimates in recent quarters. Recent news highlights its role in leading Anthropic's IPO and advancements in AI integration for wealth management.
The outlook remains positive given strong earnings momentum and strategic initiatives, though risks include volatile cash flows from operations and high leverage. Wall Street sentiment is bullish with 55.77% of analysts rating it a Buy, supporting potential upside from current levels amid broader financial sector strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →
